ESALF - Quanterix launches LucentAD biomarker test for early Alzheimer's disease

2023-07-06 18:28:00 ET

Quanterix ( NASDAQ: QTRX ) said that it has launched a biomarker blood test called LucentAD to help diagnose patients experiencing symptoms consistent with early Alzheimer's disease, or AD.

The diagnostics company said the test allows healthcare professionals to quickly assess the patient for the likelihood of amyloid pathologies associated with AD. The test will be processed by the company's CLIA labs through its new Lucent Diagnostics portal for healthcare professionals.

Earlier Thursday, the US Food and Drug Administration granted full approval to Biogen ( BIIB ) and Esai's ( OTCPK:ESALF ) ( OTCPK:ESAIY ) Leqembi, also known as lecanemab,  for the treatment of mild-to-moderate AD.

More on Alzheimer's treatments:

• Biogen, Eisai win full FDA approval for Alzheimer's drug Leqembi
• BioXcel sheds 58% as data integrity issues cloud Alzheimer’s trial win
• Cassava Sciences Alzheimer’s drug simufilam outperforms in small trial
• AC Immune gains 14% on FDA fast track tag for Alzheimer’s vaccine
• Acumen adds 14% on upcoming data for Alzheimer’s candidate

For further details see: